Cancer Network
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast CancerReal-World Evidence in NSCLC Guides Clinical Decisions Targeting NSCLC with Uncommon EGFR Mutations
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeAwareness MonthBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsMorning RoundsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Cancer Network. All rights reserved.

Advertisement
Spotlight
  • 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
  • CancerNetwork® Inaugural Face-Off
  • Contemporary Concepts in Hematologic Oncology
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
  • Real-World Evidence in NSCLC Guides Clinical Decisions
  • Targeting NSCLC with Uncommon EGFR Mutations
ClinicalSee All >
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.

Chronic Myeloid Leukemia Face-Off: Kendra Sweet, MD, on Updates in Ponatinib and Asciminib

EP. 1: How Ponatinib Factors into the Treatment of a Type of Leukemia

December 23rd 2022

Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.

EP. 2: The Implications of CML Data From ASH, And Important Takeaways for Providers

December 24th 2022

Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.

EP. 3: Highlighting Ongoing Clinical Trials in CML From ASH

December 26th 2022

Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

Advertisement
Advertisement